Seeking Alpha

Idenix Pharmaceuticals (IDIX) moves up 5.2% premarket after announcing that the FDA released a...

Idenix Pharmaceuticals (IDIX) moves up 5.2% premarket after announcing that the FDA released a partial clinical hold on the firm's study on HCV nucleotide inhibitor IDX184. The firm says the decision will allow it to expand a phase IIb program on the drug.
Comments (1)
  • EXPstocktrader
    , contributor
    Comments (388) | Send Message
     
    BofA / Merrill Lynch upgrades $IDIX near the close on Friday, Feb 3rd to $18...Holding $ACHN too for $20 buy out...Patience.
    3 Feb 2012, 04:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|